Translating insights from persistent LCMV infection into anti-HIV immunity
- PMID: 20725865
- PMCID: PMC3491651
- DOI: 10.1007/s12026-010-8162-1
Translating insights from persistent LCMV infection into anti-HIV immunity
Abstract
Human immunodeficiency virus (HIV) is a major global health concern with more than 30 million individuals currently infected worldwide. To date, attempts to stimulate protective immunity to viral components of HIV have been unsuccessful in preventing or clearing infection. Lymphocytic choriomeningitis virus (LCMV) is an established murine model of persistent viral infection that has been instrumental in illuminating several critical aspects of antiviral immunity. Although virologically the course of LCMV infection differs significantly from HIV, the immune responses and regulatory mechanisms elicited by these two viruses are markedly similar. In this review we discuss important recent findings in the LCMV model, highlighting the role of host-derived proteins in shaping immune responses to persistent infections, and explore the therapeutic potential of manipulating these pathways to enhance HIV vaccination strategies.
Similar articles
-
Interleukin-27R Signaling Mediates Early Viral Containment and Impacts Innate and Adaptive Immunity after Chronic Lymphocytic Choriomeningitis Virus Infection.J Virol. 2018 May 29;92(12):e02196-17. doi: 10.1128/JVI.02196-17. Print 2018 Jun 15. J Virol. 2018. PMID: 29593047 Free PMC article.
-
Role of viral strains and host genes in determining levels of immune complexes in a model system: implications for HIV infection.AIDS Res Hum Retroviruses. 1991 Dec;7(12):963-9. doi: 10.1089/aid.1991.7.963. AIDS Res Hum Retroviruses. 1991. PMID: 1812945
-
Immunity, immunopathology and vaccines against HIV?Vaccine. 2002 May 6;20(15):1913-7. doi: 10.1016/s0264-410x(02)00066-x. Vaccine. 2002. PMID: 11983244 Review.
-
PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.J Virol. 2020 Aug 31;94(18):e00795-20. doi: 10.1128/JVI.00795-20. Print 2020 Aug 31. J Virol. 2020. PMID: 32641478 Free PMC article.
-
Complexities of Type I Interferon Biology: Lessons from LCMV.Viruses. 2019 Feb 20;11(2):172. doi: 10.3390/v11020172. Viruses. 2019. PMID: 30791575 Free PMC article. Review.
Cited by
-
IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3.Immunol Cell Biol. 2012 Jan;90(1):124-9. doi: 10.1038/icb.2011.29. Epub 2011 Apr 26. Immunol Cell Biol. 2012. PMID: 21519345 Free PMC article.
-
Emergence of distinct multiarmed immunoregulatory antigen-presenting cells during persistent viral infection.Cell Host Microbe. 2012 May 17;11(5):481-91. doi: 10.1016/j.chom.2012.03.009. Cell Host Microbe. 2012. PMID: 22607801 Free PMC article.
-
Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice.J Exp Med. 2012 Dec 17;209(13):2485-99. doi: 10.1084/jem.20121015. Epub 2012 Dec 10. J Exp Med. 2012. PMID: 23230000 Free PMC article.
-
Blockade of chronic type I interferon signaling to control persistent LCMV infection.Science. 2013 Apr 12;340(6129):202-7. doi: 10.1126/science.1235208. Science. 2013. PMID: 23580528 Free PMC article.
-
Impaired Subset Progression and Polyfunctionality of T Cells in Mice Exposed to Methamphetamine during Chronic LCMV Infection.PLoS One. 2016 Oct 19;11(10):e0164966. doi: 10.1371/journal.pone.0164966. eCollection 2016. PLoS One. 2016. PMID: 27760221 Free PMC article.
References
-
- Gottlieb MS, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305:1425–1431. - PubMed
-
- Barre-Sinoussi F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) Science. 1983;220:868–871. - PubMed
-
- Gallo RC, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS) Science. 1983;220:865–867. - PubMed
-
- Montagnier L. 25 years after HIV discovery: prospects for cure and vaccine. Virology. 2010;397:248–254. - PubMed
-
- Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191:654–665. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
